TURNING POINT THERAPEUTICS I's ticker is TPTX and the CUSIP is 90041T108. A total of 159 filers reported holding TURNING POINT THERAPEUTICS I in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $69,117,000 | +24.1% | 918,500 | -55.7% | 0.19% | +49.2% |
| Q1 2022 | $55,715,000 | -32.6% | 2,075,037 | +19.7% | 0.13% | -18.2% |
| Q4 2021 | $82,692,000 | -19.7% | 1,733,582 | +11.8% | 0.15% | -21.4% |
| Q3 2021 | $102,992,000 | +10.4% | 1,550,383 | +29.7% | 0.20% | +12.6% |
| Q2 2021 | $93,268,000 | +1.3% | 1,195,430 | +22.8% | 0.17% | -2.2% |
| Q1 2021 | $92,053,000 | -7.1% | 973,186 | +19.6% | 0.18% | -12.3% |
| Q4 2020 | $99,121,000 | +79.1% | 813,462 | +28.4% | 0.20% | +56.2% |
| Q3 2020 | $55,335,000 | +41.1% | 633,412 | +4.3% | 0.13% | +34.0% |
| Q2 2020 | $39,211,000 | +107.0% | 607,082 | +43.1% | 0.10% | +73.2% |
| Q1 2020 | $18,941,000 | -24.0% | 424,110 | +6.0% | 0.06% | 0.0% |
| Q4 2019 | $24,916,000 | +65.7% | 400,000 | 0.0% | 0.06% | +51.4% |
| Q3 2019 | $15,040,000 | +27.3% | 400,000 | +37.7% | 0.04% | +27.6% |
| Q2 2019 | $11,819,000 | – | 290,400 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Cormorant Asset Management, LP | 2,750,000 | $260,122,000 | 5.80% |
| Burrage Capital Management LLC | 72,164 | $6,826,000 | 5.53% |
| Consonance Capital Management LP | 450,396 | $42,603,000 | 4.54% |
| MPM BioImpact LLC | 269,186 | $25,462,000 | 3.20% |
| Orbimed Advisors | 2,361,327 | $223,358,000 | 2.09% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 81,541 | $7,711,000 | 2.04% |
| SECTORAL ASSET MANAGEMENT INC | 257,879 | $24,393,000 | 1.85% |
| Nicholas Investment Partners, LP | 218,847 | $20,701,000 | 1.44% |
| Logos Global Management LP | 140,000 | $13,243,000 | 1.29% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 16,741 | $1,584,000 | 0.86% |